drugset
drugset / Trial / NCT05942612

A Phase I Study of SHR -2001 in Healthy Subjects

NCT05942612 ↗

Phase 1 Completed 72 enrolled Guangdong Hengrui Pharmaceutical Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a phase 1 single dose or multiple doses escalation study of SHR-2001 in healthy subjects. The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-2001 in healthy subjects.

Timeline

Start
2023-07-19
Primary completion
2024-11-20
Completion
2024-11-20

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-2001 Unknown — Subcutaneous

Indications

No indication recorded.